Single Cell Transcriptome in Colorectal Cancer—Current Updates on Its Application in Metastasis, Chemoresistance and the Roles of Circulating Tumor Cells

Francis Yew Fu Tieng¹, Rashidah Baharudin¹, Nadiah Abu¹, Ryia-Illani Mohd Yunos¹, Learn-Han Lee²* and Nurul-Syakima Ab Mutalib¹*

¹ UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia, ² Novel Bacteria and Drug Discovery Research Group, Microbiome and Bioresource Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Subang Jaya, Malaysia

Colorectal cancer (CRC) is among the most common cancer worldwide, a challenge for research, and a model for studying the molecular mechanisms involved in its development. Previously, bulk transcriptomics analyses were utilized to classify CRC based on its distinct molecular and clinicopathological features for prognosis and diagnosis of patients. The introduction of single-cell transcriptomics completely turned the table by enabling the examination of the expression levels of individual cancer cell within a single tumor. In this review, we highlighted the importance of these single-cell transcriptomics analyses as well as suggesting circulating tumor cells (CTCs) as the main focus of single-cell RNA sequencing. Characterization of these cells might reveal the intratumoral heterogeneity present in CRC while providing critical insights into cancer metastasis. To summarize, we believed the analysis of gene expression patterns of CTC from CRC at single-cell resolution holds the potential to provide key information for identification of prognostic and diagnostic markers as well as the development of precise and personalized cancer treatment.

Keywords: single-cell RNA sequencing, colorectal cancer, metastasis, chemoresistance, tumor heterogeneity, circulating tumor cells

INTRODUCTION

Colorectal cancer (CRC) is among major cancer worldwide in terms of incidence and mortality, with increasing trend, particularly in developing countries (Granados-Romero et al., 2017). According to global cancer statistics 2018, CRC was the third most commonly diagnosed cancer (10.2% of total cases) and ranked second for cancer-related deaths (9.2% of the total cancer deaths)

Abbreviations: CRC, Colorectal cancer; CTC, Circulating tumor cell; DNA, Deoxyribonucleic acid; ITH, Intratumoral heterogeneity; mCRC, Metastatic colorectal cancer; RNA, Ribonucleic acid; scDNA-seq, Single cell DNA sequencing; scRNA-seq, Single cell RNA sequencing; scTrio-seq, Single-cell triple omics sequencing.
(Bray et al., 2018). Approximately 30 to 50% of newly diagnosed patients will progress into metastatic CRC (mCRC) with 5-year survival rate of 50 to 60% (Arvelo, 2015; Engstrand et al., 2018). Despite the advancement in cancer detection tools and treatment options, metastasis remains a hindrance for effective treatment (Chakraborty and Rahman, 2012). Over the years, several mechanisms have been proposed to explain the metastatic progression in CRC, mainly via disturbance of cellular processes, epigenetic modifications, and genomic alterations (Herceg and Hainaut, 2007; Wong et al., 2007; Kanwal and Gupta, 2012; Arvelo, 2015). Aside from conventional treatment, in particular, chemotherapy (5-Fluorouracil, Oxaliplatin, Irinotecan and Capecitabine), many new targeted agents are also available for metastatic CRC (mCRC), including vascular endothelial growth factor (VEGF)-targeted therapy (Bevacizumab) and anti-epidermal growth factor receptor (EGFR)-targeted therapy (Cetuximab and PANitumumab) (Rihimäki et al., 2016; Burz et al., 2018). Nevertheless, metastasis remains a challenge in treating CRC, and among the main reasons are mostly attributable to intratumoral heterogeneity (ITH) and the presence of circulating tumor cells (CTCs) (Worthley and Leggett, 2010; Séronie-Vivien, 2014).

Intratumoral heterogeneity (ITH) refers to the differences in genetic and molecular characteristics between cancer cells within a single tumor or due to the various degrees of cellular differentiation (Punt et al., 2017), whereas precision treatment, often called personalized treatment, exploits patient's as well as cancer-specific molecular and pathologic signatures to target cancerous cells (Xue and Wilcox, 2016). However, in an actual scenario, not only did these precision therapies remain unresponsive to a significant amount of patients, but also promote acquired drug resistance if inhibitors were added to maximize cancer cell death at initial stage, resulting in the rapid outgrowth of resistant clones and reoccurrence of CRC (Molinari et al., 2011). One plausible explanation to this matter was that current precision medicine was tailored based on transcriptome analyses, which utilized bulk tumor data but lacked the ability to capture ITH (Valdes-Mora et al., 2018). The presence of ITH, in turn, obscured precision cancer treatment (Hutchinson, 2014; Seoane and De Mattos-Arruda, 2014). Hence, studying the cancerous cells in single-cell resolution, at molecular level, in order to understand ITH, is necessary for precision therapy and the prediction of therapeutic efficacy (Punt et al., 2017). With the recent development of high-throughput single-cell RNA sequencing (scRNA-seq), scientists now have the power to dissect the diverse cellular populations of cancers (Bagnoli et al., 2017). In the future, it is possible that the scRNA-seq technique is applied to guide the selection of targeted combination therapies and assist in determining the enrolment criteria for clinical trials.

**SINGLE CELL TRANSCRIPTOME ANALYSIS IN CRC**

At present, transcriptome analyses have been intensively applied to understand the heterogeneity of tumors via examining the gene expression level (mRNA) present in bulk tumor cell populations (Marisa et al., 2013; Sadanandam et al., 2013; Sadanandam et al., 2014). The two most recent advances in molecular pathological classification systems for CRC are The Cancer Genome Atlas (TCGA) (The Cancer Genome Atlas Network, 2012) and Consensus Molecular Subtypes (Guinney et al., 2015). The classification systems are capable of classifying tumors into subgroups with distinct molecular and establishing signatures/clinical features to predict treatment response and patient outcomes (Budinska et al., 2013; Roepman et al., 2014). Nonetheless, the overall progress is still largely hindered because of the limitation of these bulk profiling technologies in capturing ITH (Seoane and De Mattos-Arruda, 2014). Therefore, there has been rising attention in the study of single-cell transcriptomics which is capable of examining the expression levels of individual cells within a given population.

Single-cell sequencing is a powerful technology for investigating ITH by identifying genomic alterations and distinct transcriptomic states in single tumor cells (Patel et al., 2014). To date there are only a few published studies on single-cell transcriptomes of CRC. One of the first studies was published in 2017 by Li and his colleagues, which includes 11 primary CRCs (375 cells) and matched normal mucosa (215 cells) (Li et al., 2017). Single-cell RNA sequencing was performed on 969 resected primary tumor cells from 11 CRC patients, and 622 single cells from the nearby normal mucosa of seven of the patients. The authors developed a novel clustering method, named reference component analysis (RCA) and obtained seven distinct cell clusters, which were annotated as epithelial cells, fibroblasts, endothelial cells, B cells, T cells, mast cells and myeloid cells. Interestingly, although the differentially expressed genes identified by scRNA-seq and bulk analyses were significantly concordant, the majority of differentially expressed genes from scRNA-seq were undetected in bulk analysis. Epithelial–mesenchymal transition (EMT)-related genes were upregulated only in the cancer-associated fibroblast subpopulation of CRC samples. Their results indicated that via projecting bulk-tumor transcriptomes onto single-cell transcriptomes, existing CRC classification system could be further refined.

In another attempt to reveal CRC tumor heterogeneity, Ono and her coworkers combined single-cell DNA and RNA sequencing technologies with a mouse CRC model, ideal for time-series analysis (Ono et al., 2019). Single-cell exome and transcriptome sequencing of 200 cells were performed to identify ITH from one single cell. The authors demonstrated that mouse cancer cells, after undergoing alteration in transcriptional and genetic ITH, can adapt to the drastic environmental changes of allograft into a mouse. During this process, new subpopulations of cells, showing mesenchymal–epithelial transformation (MET), were generated. In addition, human CRC data from TCGA revealed a remarkable trend of metastasis in a fraction of human patients whose expression patterns were similar to those of the mouse-cell subpopulations. In a nutshell, their study revealed an evolutionary pattern of single-cell RNA and DNA changes in cancer progression and a superior CRC...
classification based on its ITH. Table 1 summarizes the recent findings from single-cell transcriptome studies in CRC.

THE NECESSITY OF SINGLE-CELL TRANSCRIPTOME ANALYSIS IN METASTATIC CRC

Majority of CRC-related deaths were related to metastatic progression (Riihimäki et al., 2016). The high metastatic rate of CRC (approximately 30 to 50%) exacerbated the situation (Engstrand et al., 2018). In this context, there is an upsurge in the discovery of new target agents for cytotoxic drugs. However, there are limited approved targeted therapy for treating mCRC, and some of these examples are EGFR monoclonal antibodies (mAbs), VEGF mAbs, anti-VEGF receptor-2 mAbs, recombinant fusion protein (Zivafibercept) and oral multikinase inhibitor (Regorafenib). The former is available for RAS wild-type patients, while the remaining are effective for those with RAS mutation (Martini et al., 2017). Unfortunately, all these treatments are unresponsive towards CRC with alterations in genes such as BRAF and PIK3CA, posing a greater risk to patients with these subtypes (Sartore-Bianchi et al., 2009; De Roock et al., 2010; Tamborero et al., 2018). Thus, new targets for drug development and techniques in identifying the complex molecular heterogeneity of mCRC, in particular, are urgently needed (Lim et al., 2019).

Single-cell transcriptomics is most likely to contribute more specific diagnostic and prognostic markers, and actionable therapeutic targets for personalized cancer medicine than bulk transcriptomics (Zhang et al., 2014). However, it was limited in terms of characterization of multiple layers of molecular features in each genetic lineage. Therefore in the year 2018, a powerful scTrio-seq (single-cell triple omics sequencing) technique was established, which was capable of examining mutations, transcriptome, and methylome simultaneously from a single cell. CRC tumors and metastases from 10 individual patients (stage III or IV) were subjected to scTrio-seq, and their analysis provided insights into tumor evolution linked DNA methylation to genetic lineages and confirmed that DNA methylation levels were consistent within lineages but can differ substantially among clones (Bian et al., 2018). To summarize, all recently conducted research converged to the necessity to tailor individualized cancer treatment based on the analysis of gene expression patterns at single-cell resolution, which hold the potential to shed light on a key mechanism behind the development of metastasis.

POSSIBLE SOLUTION TO CRC CHEMORESISTANCE

Existing advances in cancer treatment fall short of offering an adequate solution to chemoresistance, especially among patients at the advanced stages of CRC (Hammond et al., 2016). The formation of chemoresistant cells is frequently attributed to the presence of rare drug-resistant clones in the tumor before or after treatment (Shi et al., 2018). In general, these chemoresistant

| TABLE 1 | Summary of recent findings of single-cell RNA-seq and bulk analysis of CTCs in CRC. |
| Transcription Type | Sample | Finding | Citation |
|-------------------|---------|---------|----------|
| Single cell analysis | Primary CRC | Primary CRC cells from CRC patients | Development of reference component analysis (RCA) which obtained seven distinct cell clusters (epithelial cells, fibroblasts, endothelial cells, B cells, T cells, mast cells and myeloid cells). | (Li et al., 2017) |
| | Organoids from primary CRC human tumors | Detection of four newly emerged chemoresistant cell subtypes (c29, c30, c31, and c32) after Oxaliplatin treatment with different drug responses. | (Chen et al., 2018) |
| | 2824 primary CRC cells from a CRC patient | Detection of five distinct cell clusters from a CRC patient with clear sign of heterogeneity, where each cluster consisted of specific cell markers with different functions. | (Dai et al., 2019) |
| Metastatic CRC | Metastatic single cells from CRC patients | Confirmation of the feasibility of genetic lineages reconstruction together with their epigenomic and transcriptomic dynamics. Validation of the dynamics of ITH in mouse CRC models and relate to CRC in humans via comparison with TCGA data. | (Bian et al., 2018) |
| | CRC mouse model and metastatic mouse cancer cells | Identification of a total of 12 clusters corresponding to 6 cell types, including cancer cells, T cells, myeloid cells, endothelial cells, fibroblasts and B cells from patient sample of CRC liver metastasis. | (Ono et al., 2019) |
| | Samples of liver metastasis cancer tissue and adjacent tissue from CRC patients | Identification of multiple adaptive resistance mechanisms to regorafenib in CRC via single cell RNA sequencing. | (Zhang et al., 2019) |
| CRC cell line | Secondary cell line (HCT116 cells) | Identification of 410 genes related to cell movement and adhesion, cell death and proliferation, and cell signaling and interaction via cDNA microarray. | (Barbazán et al., 2012) |
| Bulk analysis | Metastatic CRC | EpCAM-based immunoisolation of CTC from 6 mCRC patients | Validation of genetically and phenotypically heterogeneity in CTC lines. Identification of gene subset commonly enriched in cultured CTC and CTCs from colon and other cancers. CTC lines expressed high levels of drug metabolism genes and were resistant to conventional therapies. | (Grillet et al., 2017) |

Frontiers in Pharmacology | www.frontiersin.org 3 February 2020 | Volume 11 | Article 135
subtypes of CRC attain the ability to disrupt drug transport, dysregulate cellular processes, alter drug sensitivity (via genetic or epigenetic modifications) and targets of therapy, that subsequently limit the efficacy of existing anti-cancer therapies (Holohan et al., 2013; Panczyk, 2014; Hu et al., 2016; Zhang and Wang, 2017; Hon et al., 2018; Abu et al., 2019). Since there are hints that metastasis and chemoresistance can be interconnected (Zheng, 2017; Durinkova et al., 2018), the previous can be prevented if chemoresistant subtypes are identified early for optimal or more aggressive treatment. Unfortunately, the mechanisms responsible for chemotherapy resistance by CRC have not been clearly identified. Moreover, current chemotherapy does not possess the strength to fully eradicate solid tumors, resulting in secondary tumor and relapse. Owing to this, numerous efforts have been made to dissect the chemoresistant cancer cells based on the genes expressions, epigenetics, pathways signatures and therapeutic responses (Datta et al., 2016; Baharudin et al., 2017; Abu et al., 2019; Li et al., 2019).

Although bulk transcriptomics is adequate to study the average gene expression signatures related to chemoresistance, they generally involve bulk tissue with assumption that all the cells obtained are of homogeneous material, thereby ignoring the stochasticity of gene expression (Raj and van Oudenaarden, 2008; Stegle et al., 2015). Single-cell transcriptomics analyses, on the other hand, are capable of studying the transcriptomes of individual cells and are more preferable for cell-specific precision therapies. For instance, a recent research by Chen et al. (2018) confirmed the capability of scRNA-seq in characterizing four different types of cellular subtypes from organoids, including drug-induced group (c29, c30, c31, and c32), drug insensitive group (c2, c5, c6, c7, c13, c22, c21, c24, c27, and c28), drug-sensitive group (c1, c3, c4, c8, c9, c11, c15, c19, c25, and c26), and drug ultrasensitive group (c10, c12, c14, c16, c17, c18, c20, c23), after treatment of Oxaliplatin. The first group displayed chemoresistance properties and appeared only after treatment. Studying of these subtypes would enable further detailed categorization based on the differential responses, genes and pathways involved, leading towards better therapeutic selection for CRC patients who might or already displayed chemoresistance before or after chemotherapy. Hence, scRNA-seq is foreseen to be applied to guide the selection of anticancer therapies and even in the prevention of chemoresistance in the future.

CTC CHARACTERISTICS AS A SNAPSHOT OF TUMOR HETEROGENEITY

Circulating tumor cells (CTCs) are rare metastatic cells shed from the primary tumor into the circulatory system, forming secondary tumor at distant tissues (Ferreira et al., 2016) (Figure 1). According to the ‘seed and soil’ hypothesis by Stephen Paget in 1889, a seed (in this case, CTC) have the ability to form metastasis only in a location suited for this process (organs like liver, lungs), whereas the mechanistic theory based on the direction of blood flow from tumor proposed by James Ewing in 1920 assumes that potential of metastasis is dependent on drainage anatomy from the primary tumor. Both these two complementary hypotheses point out the
potential of CTCs in causing metastasis during the progression of CRC. Since then, there have been several examples of validated clinical applications for CTC detection, proving its existence in CRC (Bork et al., 2015) and mCRC (Cohen et al., 2008), and also as a prognostic and predictive marker in CRC patients (Huang et al., 2014). As such, single-cell analyses of these CTCs are believed to provide critical insights into CRC cancer metastasis (Pantel and Alix-Panabières, 2012; Pantel and Speicher, 2016). However, characterization of CTCs from CRC, at the single-cell level, are as yet unknown. At present, there are only a few published papers on the bulk RNA sequencing analysis in CTCs.

As presumptive founders in the metastasis formation, CTC is becoming a field of interest, and the understanding of their biology may open new perspectives in oncology (Lim et al., 2019). In 2012, a group of Spain researchers performed molecular characterization of CTCs in human mCRC. Their objective was to investigate the biology of CTCs and improving their clinical utility in the CRC patients’ management (Barbabáñ et al., 2012). For this, EpCAM-based immunoisolation of CTC from six mCRC patients was combined with whole-transcriptome microarrays, revealing 410 genes related to cell movement and adhesion, cell death and proliferation, and cell signaling and interaction. All these genes characterized the CTC populations. Their study suggested CTCs as the diagnostic and prognostic biomarkers, which represented an innovative and promising approach in the clinical management of CRC patients in the foreseeable future.

Although CTCs have attracted a broad interest as potential markers of tumor progression and treatment response, the lack of functional characterization of these cells has become a bottleneck in taking these observations to the clinic. In addition, in vitro CTC models are lacking. Following this, Grillet and her coworkers generated several CTC lines from the blood of three advanced mCRC patients (Grillet et al., 2013). Characterization of these cells verified the presence of multipotent cells responsible for genetic and phenotypic heterogeneity, endowing them with strong metastatic potential. In addition, six genes (AGR2, CEACAM5, CLDN3, KRT18, EpCAM and FGFR3) were detected as differentially expressed in the generated CTC cell lines, which was similar to primary CRC cells grown under similar conditions (Smirnov et al., 2005; Mostert et al., 2015; Onstenk et al., 2015). The CTC lines also displayed enhanced drug/xenobiotics metabolizing activity, in particular via cytochrome P450 pathway, suggesting resistance to conventional therapies. To sum up, their study was the first experimental demonstration that CTCs isolated from mCRC patient could be used to determine drug sensitivity which aided in the formulation of personalized cancer medicine, even though the heterogeneity of CTCs was not investigated in single-cell resolution at molecular level.

**CHALLENGES AND FUTURE DIRECTIONS**

Colon is a relatively large organ, categorized into four parts (the ascending colon, the transverse colon, the descending colon and the sigmoid colon) and is composed of multiple different cells (epithelial cells, stroma, muscle cells, fat, etc.). In order to obtain a single-cell suspension, the bulk tissue has to undergo mechanical or enzymatic dissociation. Isolating the single-cell suspension containing ‘healthy’ and contamination-free viable cells are indeed a challenge for scRNA-seq studies. Moreover, there are several technical limitations in scRNA-seq like the number of cells that can be studied at a time and the depth of sequencing required. The higher the number of cells, the higher the sequencing depth needed, hence increasing the overall cost of scRNA-seq experiment. If the number of cells must be limited to a certain amount, then the overall representative of the single-cell transcriptome will be questioned. Therefore, CTCs are believed to be the versatile components which warrant a spotlight in CRC research in order to identify biomarkers that will benefit the metastatic or chemo-resistant CRC patients, while providing representative data. Also, scRNA-seq requires the cells to be intact after sorting or enrichment, prior to library preparation to prevent RNA degradation. The ability of CTCs to survive from harsh environments in the bloodstream makes them the ‘tough’ cells and the best candidate for scRNA-seq in studying CRC (Steinert et al., 2014).

At present, various technologies are developed for CTCs isolation, however, they are mainly used for research purposes rather than clinical applications (Bankó et al., 2019). Among the obstacles are the presence of ITH (Levitin et al., 2018; Lim et al., 2019), limited knowledge on CTCs mechanism of action in cancer progression (shedding from the primary/metastasis tumor, survival in bloodstream, avoidance of apoptosis, colonization potentials and settlement in distant organs), the rarity of CTCs (0 to 10 CTCs/ml whole blood in 30% to 50% mCRC patients) (Zieglschmid et al., 2013), various sizes of CTCs and the lack of clinical validation (Millner et al., 2013; Rejniak, 2016; Kovalik et al., 2017; Bankó et al., 2019). In addition, there are only a few studies relating to CTCs pharmacogenomics and underlying survival mechanisms (Wang et al., 2018) as well as the cell-cell interactions in CRC microenvironment (Krog and Henry, 2018), and majority of them are based on experimental and theoretical extrapolations (Burz et al., 2018). For instance, Yu et al. (2014) suggested that pharmacogenomic profiling of invasive CTCs could predict chemotherapy response and resistance, whereas Steinert et al. (2014) identified upregulation of CD47 in concordance with the mark down-regulation of calreticulin, which were believed to mediate immune escape and survival mechanisms of CTCs in CRC. In 2016, Ning et al. (2018) proposed CTCs as a clinically useful prognostic marker in mCRC patients as they displayed Akt-2 expression that mediated epithelial mesenchymal transition. Although CTCs demonstrated potential as a predictive marker (Yap et al., 2014) and matched most of the cancer hallmarks described by Hanahan and Weinberg (Hanahan and Weinberg, 2011; Hanahan and Weinberg, 2017; Fouad and Aanei, 2017), current understanding about their pharmacological and clinical knowledge is still limited. Therefore, we anticipate that, in the near future, with the advancement of single cell technologies, CTCs could be proven useful in CRC management and a routine screening for cancer patients.
Another bottleneck in scRNAseq is the bioinformatics data analysis. Various algorithms have been developed to infer cell types by clustering scRNAseq profiles, however, a robust algorithm is yet to be developed due to high noise levels, technical variability and batch effects (Gao, 2018; Chen et al., 2019; Choi and Kim, 2019). To date, gene expression in such tumors has been profiled using bulk transcriptome methods, providing a single transcriptome measure that represents many cell types (Barbazán et al., 2012; Grillet et al., 2017). By employing single-cell transcriptomic technology, it is now possible to deconstruct a tumor into its component cell-type parts and therefore gain a better understanding of the underlying biology. In conclusion, the analysis of gene expression patterns of CTCs from CRC at single-cell resolution holds the potential to provide key information for identification of prognostic and diagnostic markers as well as the development of precise and personalized cancer treatment.

REFERENCES

Abu, N., Hon, K. W., Jeyaraman, S., Yahaya, A., Abdullah, N. M., Mustangin, M., et al. (2019). Identification of differentially expressed circular RNAs in chemoresistant colorectal cancer. Epigenomics 11, 875–884. doi: 10.2217/epi-2019-0042
Arvele, F. (2015). Biology of colorectal cancer. cancer 9, 520. doi: 10.3332/ecancer.2015.520
Bagnoli, J. W., Wange, L. E., Janiec, A., and Enard, W. (2019). “Studying Cancer Heterogeneity by Single-RNA Sequencing,” in Lymphoma. Ed. R. Kuppers (New York, NY: Springer New York), 305–319. doi: 10.1007/978-1-4939-9151-8_14
Bahrudin, R., Ab Mutalib, N.-S., Othman, S. N., Sagap, I., Rose, I. M., Mohd Mokhtar, N., et al. (2017). Identification of predictive DNA methylation biomarkers for chemotherapy response in colorectal cancer. Front. Pharmacol. 8, 47. doi: 10.3389/fphar.2017.00047
Bankó, P., Lee, S. Y., Nagygyörgy, V., Zsényi, M., Choe, C. H., Cho, D. H., et al. (2019). Technologies for circulating tumor cell separation from whole blood. J. Hematol. Oncol. 12, 48. doi: 10.1186/s13045-019-0735-4
Barbazán, J., Alonso-Alconada, L., Muinelo-Romay, L., Vieito, M., Abalo, A., Alonso-Nocelo, M., et al. (2012). Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. PloS One 7, e40476. doi: 10.1371/journal.pone.0040476
Bian, S., Hou, Y., Zhou, X., Li, X., Yong, J., Wang, Y., et al. (2018). Single-cell mulomics sequencing and analyses of human colorectal cancer. Science 362, 1060–1063. doi: 10.1126/science.aao3791
Bork, U., Rahbani, N., Schölich, S., Reissfelder, C., Kahler, C., Büchler, M. W., et al. (2015). Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br. J. Cancer 112, 1306–1313. doi: 10.1038/bjc.2015.88
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clin. 68, 394–424. doi: 10.3332/caac.214922
Budinska, E., Popovic, V., Teijpar, S., D’Ario, G., Lapiche, N., Sikora, K. O., et al. (2013). Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J. Pathol. 231, 63–76. doi: 10.1002/path.4212
Burz, C., Pop, V.-V., Buiga, R., Daniel, S., Samasca, G., Aldea, C., et al. (2018). Circulating tumor cells in clinical research and monitoring patients with colorectal cancer. Oncotarget 9, 24561–24571. doi: 10.18632/oncotarget.25337
Chakraborty, S., and Rahman, T. (2012). The difficulties in cancer treatment. cancer 6, 1–5. doi: 10.3332/ecancer.2012.ed16
Chen, K., Srinivasan, T., Lin, C., Tung, K., Gao, Z., Hsu, D. S., et al. (2018). Single-cell transcriptomics reveals heterogeneity and drug response of human colorectal cancer organisms, in: 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). Conf. Proc. IEEE Eng. Med. Biol. Soc. 2378–2381. doi: 10.1109/EMBC.2018.8512784
Chen, G., Ning, B., and Shi, T. (2019). Single-Cell RNA-Seq technologies and related computational data analysis. Front. Genet. 10, 317. doi: 10.3389/fgene.2019.00317
Choi, Y. H., and Kim, J. K. (2019). Dissecting cellular heterogeneity using single-cell RNA sequencing. Mol. Cells 42, 189–199. doi: 10.14348/molcells.2019.2486
Cohen, S. J., Punt, C. J., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., et al. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 3213–3221. doi: 10.1200/JCO.2007.13.8923
Dai, W., Zhou, F., Tang, D., Lin, L., Zou, C., Tan, W., et al. (2019). Single-cell transcriptional profiling reveals the heterogeneity in colorectal cancer. Mol. (Baltimore) 98, e16916. doi: 10.1097/MID.00000000000016916
Datta, A., Dey, S., Das, P., Alam, S. K., and Roychoudhury, S. (2016). Transcriptome profiling identifies genes and pathways deregulated upon fluorouridine treatment in colorectal cancer cells harboring GOF mutant p53. Genomics Data 8, 47–51. doi: 10.1016/j.gdata.2016.03.003
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., et al. (2010). Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11, 753–762. doi: 10.1016/S1470-2045(10)70130-3
Durimikova, E., Kozovska, Z., Poturnajova, M., Plava, J., Cierna, Z., Babelova, A., et al. (2018). ALDH1A3 upregulation and spontaneous metastasis formation is associated with acquired chemoresistance in colorectal cancer cells. BMC Cancer 18, 848. doi: 10.1186/s12885-018-4758-y
Engristrad, J., Nilsson, H., Strömbom, C., Jonas, E., and Freedman, J. (2018). Colorectal cancer liver metastases – a population-based study on incidence, management and survival. BMC Cancer 18 (1), 78. doi: 10.1186/s12885-017-3925-x
Ferreira, M. M., Ramani, V. C., and Jeffrey, S. S. (2016). Circulating tumor cell RNA sequencing. Front. Genet. 7, 68. doi: 10.3389/fgene.2016.00037
Foud, Y. A., and Aanei, C. (2017). Revisiting the hallmarks of cancer. Am. J. Cancer Res. 7, 1016–1036.
Gao, S. (2018). Data analysis in single-cell transcriptome sequencing. Methods Mol. Biol. 1754, 311–326. doi: 10.1007/978-1-4939-7717-8_18
Granados-Romero, J. J., Valderama-Tresvino, A. 1. L, Contreras-Flores, E. H., Barrera-Mera, B., Herrera Enríquez, M., Uriarte-Ruíz, K., et al. (2017). Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J. Pathol. 231, 63–76. doi: 10.1002/path.4212
Grillet, F., Bayet, E., Villeron, O., Zappia, L., Lagerqvist, E. L., Lunke, S., et al. (2017). Circulating tumour cells from patients with colorectal cancer have human colorectal cancer.
Steinert, G., Scholch, S., Niemietz, T., Iwata, N., García, S. A., Behrens, B., et al. (2014). Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res. 74, 1694–1704. doi: 10.1158/0008-5472.CAN-13-1885

Tamborero, D., Rubio-Perez, C., Deu-Pons, J., Schroeder, M. P., Vivancos, A., Rovira, A., et al. (2018). Cancer genome interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 10, 25. doi: 10.1186/s13073-018-0531-8

The Cancer Genome Atlas Network. (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337. doi: 10.1038/nature11252

Valdes-Mora, F., Handler, K., Law, A. M. K., Salomon, R., Oakes, S. R., Ormandy, C. J., et al. (2018). Single-cell transcriptomics in cancer immunobiology: the future of precision oncology. Front. Immunol. 9, 2582. doi: 10.3389/fimmu.2018.02582

Wang, W.-C., Zhang, X.-F., Peng, J., Li, X.-F., Wang, A.-L., Bie, Y.-Q., et al. (2018). Survival mechanisms and influence factors of circulating tumor cells. BioMed. Res. Int. doi: 10.1155/2018/6304701

Wong, J. J. L., Hawkins, N. J., and Ward, R. L. (2007). Colorectal cancer: a model for epigenetic tumorigenesis. Gut 56, 140–148. doi: 10.1136/gut.2005.088799

Worthley, D. L., and Leggett, B. A. (2010). Colorectal cancer: molecular features and clinical opportunities. Clin. Biochem. Rev. 31, 31–38.

Xue, Y., and Wilcox, W. R. (2016). Changing paradigm of cancer therapy: precision medicine by next-generation sequencing. Cancer Biol. Med. 13, 12–18. doi: 10.28092/j.issn.2095-3941.2016.0003

Yap, T. A., Lorente, D., Ormlin, A., Olmos, D., and de Bono, J. S. (2014). Circulating tumor cells: a multifunctional biomarker. Clin. Cancer Res. 20, 2553–2568. doi: 10.1158/1078-0432.CCR-13-2664

Yu, K. H., Ricigliano, M., Hidalgo, M., Abou-Alfa, G. K., Lowery, M. A., Saltz, L. B., et al. (2014). Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. Clin. Cancer Res. 20, 5281–5289. doi: 10.1158/1078-0432.CCR-14-0531

Zhang, Y., and Wang, J. (2017). MicroRNAs are important regulators of drug resistance in colorectal cancer. Biol. Chem. 398, 929–938. doi: 10.1515/hbz-2016-0308

Zhang, S., Wei, J. S., and Khan, J. (2014). “The Significance of Transcriptome Sequencing in Personalized Cancer Medicine,” in (Cancer Genomics: Elsevier), 49–64. doi: 10.1016/B978-0-12-396967-5.00004-9

Zhang, Y., Song, J., Zhao, Z., Yang, M., Chen, M., Liu, C., et al. (2019). Single-cell transcriptome analysis reveals tumor immune microenvironment heterogeneity and granulocytic enrichment in colorectal cancer liver metastases. Cancer Lett 470, 84–94. doi: 10.1016/j.canlet.2019.10.016

Zheng, H.-C. (2017). The molecular mechanisms of chemoresistance in cancers. Oncotarget 8, 59950–59964. doi: 10.18632/oncotarget.19048

Zieglschmid, V., Vollmann, C., and Böcher, O. (2005). Detection of disseminated tumor cells in peripheral blood. Crit. Rev. Clin. Lab. Sci. 42, 155–196. doi: 10.1080/10408360590913696

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Tieng, Baharudin, Abu, Mohd Yunos, Lee and Ab Mutalib. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.